Education
About Us
Working with TipRanks
Follow Us
Femasys, Inc. (FEMY)
NASDAQ:FEMY
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$0.31 - $1.76
Previous CloseN/A
Volume25.00K
Average Volume (3M)579.33K
Market Cap
$33.91M
Enterprise Value$20.64M
Total Cash (Recent Filing)$4.57M
Total Debt (Recent Filing)$8.43M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 26, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding59,501,854
10 Day Avg. Volume350,649
30 Day Avg. Volume579,331
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)10.63
Price to Sales (P/S)15.04
P/FCF Ratio-1.21
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue10.01
Enterprise Value/Gross Profit23.62
Enterprise Value/Ebitda-1.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$7.55M
Bulls Say, Bears Say
Bulls Say
Regulatory Clearance (FemVue)510(k) clearance for FemVue materially improves U.S. market access for a diagnostic platform that integrates prior technologies. This reduces regulatory barriers, supports clinical adoption across fertility workflows, and enables incremental recurring consumable sales and streamlined manufacturing.
European Commercialization And DistributionSecuring regional distributors and executing launches in multiple European markets creates durable revenue channels, leverages partners' clinical relationships, and validates product-market fit abroad. Initial commercial orders (e.g., FemBloc) indicate tangible demand and support scale in core international markets.
Improved Leverage ManagementA materially lower debt-to-equity ratio reflects better leverage control and reduces near-term solvency pressure. Improved capital structure increases financial flexibility to fund commercialization and absorb operating losses without immediate distress, supporting execution over coming quarters.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flows limit internal funding for commercialization and working capital needs. The company remains dependent on external financing, increasing dilution and execution risk if capital markets tighten or planned offerings underperform in the next several quarters.
Persistent Unprofitability And Margin ErosionNegative and deteriorating margins indicate weak unit economics or rising costs that undermine sustainable profitability. Without margin recovery via pricing, mix, or cost control, the company faces structural challenges converting revenue growth into positive operating results and shareholder returns.
Nasdaq Listing-compliance RiskActive listing noncompliance and the potential need for a reverse split are structural governance and market-access risks. A forced corporate action could dilute liquidity, disrupt investor relations, and distract management from commercialization priorities until compliance is achieved.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $0.31 and its highest was $1.76 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $33.91M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 24 days.
How were Femasys, Inc.’s earnings last quarter?
Femasys, Inc. released its earnings results on Nov 14, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.115 by $0.015.
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Overvalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 59,501,854 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Femasys, Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.115. Following the earnings report the stock price went up 8.596%.
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Femasys Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
FEMY Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.21%
12-Months-Change
Fundamentals
Return on Equity
-376.23%
Trailing 12-Months
Asset Growth
4.52%
Trailing 12-Months
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
3.06% Insiders
1.89% Mutual Funds
1.11% Other Institutional Investors
91.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---